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or double-blind study protocols. The purpose of the present trial was to compare the changes in visceral fat (primary endpoint) and other parameters between the use of formula foods containing soy protein (SP) and those containing milk protein (MP) in a randomized, double-blind, controlled, comparative trial.
Methods

Subjects
This trial was conducted at Fukuoka University Hospital in Japan. The protocol was approved by the Independent Review Board (IRB) of Fukuoka University Hospital [No. 7-006(7-34) ]. At the beginning of the trial, Fukuoka University Extension Center contacted citizens of Fukuoka City (Nanakuma area) by advertising the research protocol, and the details of the trial were described. Seventy-seven subjects who applied were screened, and 29 subjects (25 had low visceral fat on computed tomography (CT), 3 declined participation, and 1 was considered ineligible by the investigators) were excluded (Figure 1) . Ultimately, 48 obese Japanese adults (aged 22-72 years) were enrolled. Each subject signed an informed consent form after the protocol was explained. A subject was eligible for inclusion if all of the following criteria were met: visceral fat area ≥100 cm 2 as estimated on CT at the level of the navel; outpatient aged 20-75 years; and able to consume a formula shake. A subject was not eligible for inclusion if any of the following criteria were met: secondary obesity; abnormal level of free T4, thyroid-stimulating hormone, or cortisol; pregnancy; breast-feeding; history of treatment with systemic steroid hormone, hormone replacement; thiazolidine derivative, insulin, sulphonyl urea, α-and β-blockers, diuretics, drugs for thyroid dysfunction and others that may influence body weight (BW) as noted in the drug information within the previous 12 weeks; psychosis; use of antipsychotic, antidepressant, or anti-manic drugs, alcohol or substance abuse; smoking cessation within the previous 6 months or planning to stop or reduce smoking; type 1 diabetes mellitus; uncontrolled type 2 diabetes mellitus (hemoglobin A1c (HbA1c) >8.0% as defined by the Japan Diabetes Society [JDS]); moderate to severe renal disease (creatinine [Cr] >1.5-fold upper limit); heart failure; severe hepatic disease; history of malignancy within the past 5 years; severe autoimmune disease; pathological edema or body fluid; gastrointestinal disease that could influence food absorption; history of gastrointestinal operation or myocardial infarction; stroke within the past 6 months; allergy to soy bean or milk; absence of a 3-timesdaily dietary habit; night duty more than 3 times per week; lifestyle change of more than 2 weeks; and enrollment in another clinical trial. 
Protocol
The trial formula food contained SP (ObeCure ® , USCare, Inc., Japan). In the control formula food, SP was replaced with MP (skim milk; Table 1 ). Some MP is needed to dissolve SP (ObeCure ® ) in water (SP group); that is, the soy-based formula food must contain MP. The control formula food (MP) contains more calcium, phosphorus, and potassium because SP has been replaced by MP. Each formula food contains 170 kcal/pack. Japanese Food Research Laboratories analyzed samples of each of the formula foods and estimated that the calories based on composition were 381 kcal/100 g for ObeCure ® and 374 kcal/100 g for the control formula food. The used package and unused formula food were collected at the next visit.
This was a randomized, double-blind, controlled, parallel trial. After prescreening, the 48 subjects were assigned to a soy-based formula food group (SP group) or the control group (MP group) with a male/female ratio of 1:3. In each group, for 20 weeks, breakfast was replaced by the respective formula food dissolved in 250 ml water. The subjects were assigned to groups using computer randomization by an independent person at the Clinical Research Assist Center at Fukuoka University Hospital. Several reports have indicated that such replacement in the morning was superior to that in the afternoon or evening. 14 After the trial period, the subjects had a regular breakfast and were followed for another 12 weeks (Figure 1 ; week 32). The subjects were advised to maintain their usual diet except for use of the formula food. During the trial period, the subjects recorded their food and drink intake for 3 days before their visits on weeks 0, 12, 20, and 32, and were instructed on how to prepare records at the beginning of the study. Caloric intake was estimated from these records by a registered dietician using the Food Exchange List: Dietary Guidance for Persons with Diabetes edited by the JDS, standard tables of food composition in Japan (5 th edition, revised). The investigator (physician) instructed the subjects not to change their physical activity throughout the study period and confirmed levels of physical activity during the study by questionnaires. Thus, as an exclusion criterion, participants who changed their lifestyle for more than 2 weeks were removed from the study.
Measurements
Visceral fat was estimated on CT at the level of the navel. Visceral and subcutaneous fat area and body circumference were measured by a estimator who was blinded to the group assignment, using FatScan (N2 System, Hyogo, Japan) at 0, 12, and 20 weeks, as described previously. 6 BW and the body fat ratio were measured with a scale (Karada Scan HBF-362, Omron, Japan) every 4 weeks during the trial period without clothes other than underwear and a hospital gown. The waist circumference was measured halfway between the lower rib and iliac crest at the level of the navel. Blood pressure and pulse rate were measured every 4 weeks during the trial period.
Serum levels of triglyceride, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), apolipoprotein (apo) A-I, apo B, glucose, HbA1c (JDS value), aspartate aminotransferase (AST), alanine aminotransferase (ALT), Cr, insulin, adiponectin, leptin, and tumor necrosis factor (TNF)-α were measured after an overnight fast at 0, 20, and 32 weeks at the Fukuoka University Hospital Laboratory Unit or by SRL Corporation.
Statistical Analysis
Data are presented as mean ± SE. The significant changes in continuous variables during the study period for the SP and MP groups were examined on analysis of covariance (ANCOVA) using a general linear model (GLM) for unbalanced longitudinal data while controlling for between-subject variation. Significant changes from baseline at 12 and 20 weeks were also examined using the GLM without excluding subjects who dropped out. The between-group effects and the interaction between the group and study period were examined using a random effects (mixed effects) model. Profiles of log-transformed visceral fat measured at 0 and 20 weeks were compared among the 2 experimental groups by applying a mixed-effects model adjusting for baseline visceral fat. SAS 9.2 for Windows was used for the statistical analysis. P<0.05 was considered to be statistically significant.
Results
Subjects
Forty-eight subjects (12 men and 36 women, age 22-72 years) were enrolled in the trial. In the SP group, a female subject at 12 weeks, a male subject at 20 weeks and a female subject at 32 weeks were withdrawn. In the MP group, a male subject was withdrawn at 32 weeks. The withdrawals were not related to an adverse reaction to the formula diet or to a change in physical activity. Tables 2,3 list subject characteristics. The compliance for formula food intake was 95% in the SP group and 95% in the MP group based on a calculation of the used empty packages and unused formula food packages collected at each visit.
Primary Endpoint: Changes in Visceral Fat Area
The SP and MP groups did not differ significantly in age, BW, BMI, body fat ratio, visceral fat area, or waist circumference at 0 weeks ( Table 2) . During the 20-week trial period, visceral fat area and subcutaneous fat area in the MP group were significantly reduced, while those in the SP group did not change significantly (Table 2; Figures 2B,C) as assessed on ANCOVA. There was a significant interaction effect between the group and trial period for the visceral fat area as assessed in the mixed effects model (data not shown), indicating that the SP and MP groups had different patterns of changes in visceral fat area ( Figure 2B ).
Other Physical Measurements
During the 20-week trial period, although waist circumference was reduced in both the SP and MP groups, BW and BMI were significantly reduced only in the MP group ( Table 2 ; Figure 2A ), as assessed on ANCOVA. At 32 weeks (12 weeks after the trial foods were stopped), however, both the SP and MP groups showed significant reductions in waist circumference, BW, and BMI compared to 0 weeks ( Table 2 ). The body fat ratio was significantly reduced in the MP group but not in the SP group during the trial period ( Table 2) . Systolic blood pressure was decreased in the MP group and diastolic blood pressure was decreased in the SP group ( Table 2) . Pulse rate did not change significantly in either groups during the trial period. Between-group differences and interaction effects between group and waist circumference, BW, BMI, or body fat ratio were not significant as assessed in the mixed effects model (data not shown).
Laboratory Data
At the end of the trial period (20 weeks), HbA1c (JDS value) was decreased in the MP group, and the adiponectin concentration was increased in both the SP and MP groups ( Table 3) , as assessed on ANCOVA. Other measured variables, that is, levels of fasting plasma glucose, insulin, triglyceride, LDL-C, HDL-C, apo A-I, apo B, leptin, TNF-α, AST, and ALT, did not change significantly in either groups during the 20 weeks of the trial period ( Table 3) . At 32 weeks, apoA-I in the SP group was significantly higher than that at 0 weeks. Significant changes in fasting plasma glucose, HbA1c, insulin, and adiponectin in the MP group and leptin in the SP group were observed after the trial food was stopped (32 weeks vs. 20 weeks). Table 4 compares the patterns of changes in visceral fat area in the SP and MP groups using the mixed effects model after controlling for baseline visceral fat area and other factors that may affect visceral fat area. The interaction effect between the group and study period for visceral fat area was significant ( Table 4 ), indicating that the difference in the patterns of changes in visceral fat area in the SP and MP groups ( Figure 2B ) was independent of these factors that may affect visceral fat area.
Visceral Fat Area and Risk Factors
Calorie Intake
In a time-course comparison, only calorie intake at 20 weeks was significantly lower than that at 0 weeks in the MP group. ). There were no significant differences in compliance with taking the formula food during the study period between the 2 groups.
Safety
Other than unrelated events, there were 20 adverse events (6 gastrointestinal disorders and 14 laboratory test) in the SP group and 11 (5 gastrointestinal disorders and 6 laboratory tests) in the MP group. There was no difference in the frequency of adverse events between the groups. None of these events was related to withdrawal from the trial. 
Discussion
The prevalence of visceral fat obesity is a growing research area, and formula food is one of the approaches that is being used to reduce visceral fat. 15-17 Formula food with limited fat and carbohydrate, but which is rich in protein, vitamins, and minerals, has been reported to be effective at reducing BW. 15-17 In particular, SP has been reported to be a potent factor in treating overweight subjects, 12,18 but these results have not been verified in well-randomized study protocols.
To clarify the efficacy of soy at reducing visceral fat, we carried out a randomized, double-blind, controlled, comparative trial that compared formula food containing SP to the same food in which soy was replaced by MP. 3446 † Assessed on analysis of covariance after controlling for covariates using mixed effects model. Group and sex were included in the mixed effects model as dummy variables. For group, 1=SP group, 0=MP group; for sex, 1=male, 0=female. Data at 0 and 20-weeks were analyzed. Group × period indicates the interaction between group and study period, and group × adiponectin indicates the interaction between group and adiponectin. CI, confidence interval; HOMA-IR, homeostasis model assessment of insulin resistance. Other abbrteviations see in Tables 1,2 
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The primary endpoint was change in the visceral fat area as estimated on CT because an accurate diagnosis of metabolic syndrome requires the estimation of visceral fat. In contrast to our hypothesis, the consumption of formula food containing MP in the morning decreased visceral fat after 20 weeks, and this reduction was significantly greater than that in subjects who consumed formula food containing SP.
During the 20-week trial period, visceral fat area and subcutaneous fat area in the MP group were significantly reduced, while those in the SP group did not change as assessed on ANCOVA ( Table 2) . Although waist circumference was reduced in both the SP and MP groups, BW and BMI were significantly reduced only in the MP group ( Table 2 ). The significant difference in the visceral fat area at 20 weeks between the MP and SP groups (mean, 129.2 cm 2 vs. 150.9 cm 2 , respectively) probably reflects the significant reductions in BW and BMI in the MP group.
Several clinical trials that have compared SP and MP have found no differences in weight reduction. 13,19, 20 Anderson et al compared the visceral fat area as estimated on CT in obese women who consumed soy and casein shakes as part of a calorie-restricted diet for 21 weeks. 21 Both were effective in reducing the visceral fat area, and there was no significant difference between the groups. High-intensity weight-loss interventions may decrease the likelihood of detecting significant differences between experimental arms. In the present trial there was no weight-loss intervention and there was no difference in daily caloric intake during the trial period between the groups, as described here. Recently, Liu et al reported that SP with or without isoflavone did not have favorable effects on glycemic control and insulin sensitivity, even though BW was not changed at 6 months among Chinese women in a randomized, placebo-controlled trial. 22 These data indicate that formula food containing MP is superior to the same food containing SP for reducing visceral fat.
Five grams of β-conglycinin, a SP isolate, has been reported to reduce both the visceral fat area by approximately 5% as estimated on CT, and BW after 12 weeks, while casein, the major MP, did not reduce the visceral fat area. 12 The soybased formula food in the present trial consisted of 12 g of SP, which contains 1.5-2.0 g of β-conglycinin. The difference in the amounts of β-conglycinin may lead to different results.
In general, MP consists of 80% casein and 20% whey, and the formula food that contained MP also contained whey. Whey contains α-lactoglobulin, β-lactoglobulin, proteose, and peptone. Whey has been reported to reduce BW, serum cholesterol, and triglyceride in rodents 23 and human subjects after 12 weeks in a randomized, double-blind, controlled study. 24 Lactoferrin, lactoalbumin, and lactoglobulin may play important roles in weight reduction and the improvement of hyperlipidemia. 25 Because the formula food that contained SP also contained 9 g of MP, further experimental studies will be needed to determine the appropriate dose of MP. An increased consumption of milk has been reported to reduce BMI. 26 A milk product reduced visceral fat under a calorie-restricted diet in 32 obese subjects. 27 The mechanism by which milk contributes to weight reduction may involve calcium supplementation. In the present trial the formula food with MP contained more calcium than the SP formula food (500 mg vs. 330 mg) after both formulas were adjusted to have the same amount of protein. Although this may have influenced weight reduction, a high-calcium diet containing 800 mg or 1,200 mg calcium per day produced significantly greater weight reduction than a diet containing 400-500 mg calcium, 27 and thus the range of 300-500 mg calcium per day in the present trial may have had a negligible effect.
Adiponectin is secreted from fat cells and has several beneficial effects, such as enhancing glucose uptake into skeletal muscle, increasing fatty acid oxidation, decreasing gluconeogenesis in hepatic cells, suppressing fat accumulation and fibrosis, decreasing foamy cell formation from macrophage, suppressing endothelial thickening, and promoting antioxidation. 28- 31 The use of a formula food has been reported to increase the level of adiponectin. 32 Figure 3 shows the Table 4 ) and adiponectin (μg/ml), from baseline to 20 weeks (baseline value minus that at 20 weeks). Pearson's correlation coefficient was obtained. Although an increase in adiponectin with a reduction in visceral fat was observed (r=-0.93, P<0.0001) in the (B) control (milk protein) group, there was no significant correlation in the (A) soy protein group (r=0.139, P=0.55). TAKAHIRA M et al.
changes in visceral fat and adiponectin from baseline to 20 weeks. An increase in adiponectin with a decrease in visceral fat was observed in the MP group but not in the SP group. Therefore, MP may play some role in the interaction between visceral fat and adiponectin through some unknown mechanism(s). Adiponectin has also been reported to regulate HDL-C levels, 33 but no changes or relationships were observed between HDL-C and apo A-I levels and adiponectin in the present trial. Varady et al reported that a minimum weight loss of 5% is required to improve the adipokine profile and fat cell size, 34 and thus not only visceral fat but also a change in BW may influence metabolic parameters.
A weight gain after weight reduction has been reported to be rare with the use of a formula food. 35 Subjects who used the formula food containing MP did not gain weight 3 months after the trial. Although the mechanism is unclear, serum ketone produced by fatty acid oxidation during the calorie-restricted period using formula food might suppress the feeling of hunger even after the intake of formula food, or the motivation for calorie restriction and the desire for weight loss may continue after the long-term trial. During the follow-up period (32 weeks), the reductions in waist circumstance, BW, and BMI were maintained in both groups ( Table 2 ). The aim in the follow-up period was to observe rebound phenomena. Although the participants' lifestyles were not monitored during this period (20-32 weeks), most had tried to reduce their BW in their own way, and this is one of the reasons why both groups showed reductions in these parameters (vs. 0 weeks), while no significant differences in such parameters were observed between the 2 groups at week 32.
In addition, in intervention studies for obesity using formula food the age of the participants is not limited because the possible mechanism for weight reduction is not hormone dependent. The similar studies included subjects in their teens to 60 s, 12,20,21 and thus the enrollment criteria for age may not be critical in the present study.
Study Limitations
Although the sample size of 48 subjects is small, to the best of our knowledge this is the first, randomized placebo-controlled prospective comparative trial using formula food. Commercially available soy-based formula food was chosen as an interventional method, and has already been shown to be associated with significant weight reduction in clinical trials when used to replace breakfast. This formula includes 9 g of MP to promote the solubility of SP in water, as would sugar or dextrin, and so on. For a direct comparison of SP and MP, a new method is needed to produce pure SP formula food. The total intake of SP and MP, not only from formula food but from the entire diet before and during the study period, should be monitored to better understand the present results in greater detail. Although dietary calorie intake was monitored in this program, physical activity was not monitored using a quantitative method. The investigator (physician) instructed the subjects, however, to not change their physical activity during the study period at the onset of study and at every patient visit. According to the exclusion criteria, if a participant changed their lifestyle for more than 2 of the 20 weeks, they were to be removed from the study. But none of the subjects was excluded from the study for this reason.
In conclusion, a formula food containing MP was superior to a formula food containing SP when used to replace breakfast for the reduction of visceral fat. Although the formula food containing MP reduced visceral fat by approximately 15% over 20 weeks, the visceral fat area as estimated on CT was >100 cm 2 at 20 weeks in all of the present patients. If the effective MP element can be isolated, a more effective formula food may be created, and this could make it possible to reduce visceral fat more efficiently and improve metabolic syndrome.
